P53 mutation linked to advanced CRC in African-Americans

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 4
Volume 18
Issue 4

Researchers have identified a possible genetic cause for an increased risk for a more advanced form of colorectal cancer in blacks that leads to shorter survival, according to data published in Clinical Cancer Research (15:2406-2416, 2009).

Researchers have identified a possible genetic cause for an increased risk for a more advanced form of colorectal cancer in blacks that leads to shorter survival, according to data published in Clinical Cancer Research (15:2406-2416, 2009).

Upender Manne, PhD, and colleagues at the University of Alabama in Birmingham analyzed 137 colorectal adenocarcinomas from African-American patients and 236 colorectal adenocarcinomas from non-Hispanic whites. Researchers assessed these carcinomas for p53 mutations and genotyped for codon 72 polymorphisms.

Overall, whites and African-Americans had a similar rate of p53 mutations. However, the frequency of the Pro72 allele was higher in blacks (17%) compared with 7% among whites. By contrast, the Arg72 allele frequency was higher in whites (36%) than in African-Americans (19%).

Presence of the Pro72 allele in blacks was associated with a more than two-fold increase in mortality due to colorectal cancer (See “Minority groups protest CMS rejection of VC screening,” page 35).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.